Blog

US telehealth giant Hims &amp; Hers’ USD 1.15bn acquisition in February of Australian digital health company Eucalyptus is expected to significantly shake up the international digital health sector. The deal, set to close in mid 2026, has certainly caused a stir in Australia, where it is by far the largest acquisition of a preventative healthcare company.Pinning down precise transaction multiples is difficult given the deal’s limited valuation disclosure. But the “up to USD 1.15bn” consideration, which was based on a run‑rate derived from January 2026 revenue, and triple‑digit, year-over-year, quarterly ARR growth through 2025, implies a mid‑ to high‑single‑digit historic revenue multiple and a sizeable payday for Eucalyptus’ founder Tim Doyle and his private equity backers.This multiple is at the upper end of prevailing sector benchmarks. Nelson Advisors’ January 2026 HealthTech valuation report puts general digital health assets at 4x-6x revenue. But the report notes that premium telehealth and AI‑enabled platforms – those showing strong growth and embedded workflows – command 6x-8x+ revenue multiples.The deal valuation will have caught the attention of other players and investors in Australia’s burgeoning preventative medicine sector, which is already well known for its strong foundation in biotech, innovative digitally-driven health and AI-powered diagnostics.Sector stakeholders will also have noted the wider implications of the Eucalyptus deal, which Nelson Advisors said has turned Hims &amp; Hers into an international “powerhouse” and “represents one of the most significant consolidations in the history of the [global] telehealth industry”.Source: <a href="https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/">https://ionanalytics.com/insights/mergermarket/hims-hers-usd-1-15bn-eucalyptus-deal-signals-new-era-for-australias-digital-health-dealspeak-apac/</a>

Nelson Advisors featured in Mergermarket: Hims & Hers’ $1.15 Billion Eucalyptus deal signals new era for Australia’s Digital Health

Major themes this week: EU‑level regulatory moves (MDR/IVDR and AI Act alignment), fresh EU digital/health funding instruments, and continued capital flowing into European digital health, with France and Germany especially active.EU regulation and policy The Commission’s 2026 “Health Package” is moving forward with revisions to MDR/IVDR to ease bottlenecks, including more predictable conformity assessments, a codified Helsinki procedure for borderline products, and risk‑based certificate validity rather than fixed terms. Work continues on aligning AI Act “high‑risk” obligations with MDR/IVDR so high‑risk medical AI can follow a single sectoral route instead of duplicated certification, with core AI Act obligations expected to bite around August 2026. EU‑level HTA machinery is now live, with more MedTech expected into joint clinical assessments in 2026, raising the evidentiary bar for pan‑EU digital and AI‑enabled devices. Data protection bodies (EDPB/EDPS) issued a joint opinion on the proposed European Biotech Act this month, signalling closer scrutiny of data‑intensive biotech and digital health models. Public funding and grant landscape Within Horizon Europe 2026–27, a substantial part of a €14bn R&amp;I envelope is earmarked for health and digital technologies, reinforcing medium‑term support for AI, data and platform‑driven health innovation. EIT Health’s 2026 Innovation Validation Call launched, co‑funding up to 50% of late‑stage digital/data/AI health projects (cap €850k) to accelerate clinical validation, regulatory approval, and market launch. Global Health EDCTP3 opened 2026 calls with up to €147m across six topics (TB, LRTIs, HIV, climate‑linked infectious disease), all with clear digital and AI platform angles, plus a joint call offering up to €2.25m per project for digital/AI health research in Sub‑Saharan Africa. Under the Digital Europe Programme, the DIGITAL‑2026‑SKILLS‑09 call closed with 31 proposals received by 3 March, focusing on advanced digital skills, which is relevant for AI and data‑heavy health ecosystems. Private capital and market sentiment In the week of 14–21 March, Europe growth‑stage startups raised about $2.11bn, with notable health‑adjacent raises such as Alan’s €100m round to scale its digital health insurance and services platform. Broader context: February 2026 saw European digital health record roughly $318m across 18 deals, a recalibration from January but interpreted as capital “holding its nerve” rather than exiting the category, with more selectivity around evidence and path to profitability. Analysts note a pivot from early‑stage experiments towards validation‑stage digital health and AI, with capital and public instruments concentrating on companies that are closer to clinical proof and commercial scaling.Ecosystem and NHS‑related signals EU‑level and national fora (e.g., health.tech Basel, Masters of Digital 2026) are increasingly focused on moving from pilots to execution, highlighting AI deployment, prevention systems and digital clinical trials.In the UK, Digital Health Rewired 2026 (this week at the NEC) is spotlighting themes such as integrated care, prevention, and EPR optimisation, framed against a £10bn NHS tech investment programme and ~90% EPR adoption in England. Prior DHSC announcements about 45 NHS remote‑monitoring pilots via the NHS App (targeting ~500k appointments freed per year) remain a reference point for scaling virtual care and self‑reporting tools into mainstream pathways.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>&gt;&gt;&gt;&gt;Headline moves in European MedTech this week centre on MDR/IVDR overhaul, EU–Switzerland mutual recognition, and a steady drumbeat of consolidation‑driven dealmaking and infrastructure‑type funding.Regulation: MDR/IVDR “reset” and digitisation The Commission has now formally proposed an MDR/IVDR overhaul aimed at simplifying procedures, easing notified‑body bottlenecks, and reducing shortage risk, with adoption targeted around summer 2026. Key elements include more proportionate clinical evidence requirements for legacy/low‑risk devices, streamlined renewals, and better transition pathways, framed explicitly as pro‑innovation while preserving safety. Parallel legal analysis highlights planned digitisation of compliance: declarations of conformity and certain IFUs in digital form only, mandatory electronic submissions, and digital contact details in EUDAMED (new MDR Art. 110a; IVDR Art. 103a). EU–Switzerland medical devices détente On 2 March, the EU and Switzerland agreed a package updating their Mutual Recognition Agreement, a major political step towards restoring mutual recognition for medical devices after several years of “third‑country” treatment. This is expected to stabilise market access and regulatory cooperation, reducing duplicative conformity assessments and administrative friction for EU and Swiss MedTech exporters. Market structure, risk and M&amp;A tone Sector commentary for 2026 continues to stress “regulation, risk and resilience”: sustained demand and strong fundamentals, but higher compliance costs driving portfolio pruning and reprioritisation of launches. Distressed M&amp;A is framed as a structural feature of 2026 European MedTech, driven by regulatory capital requirements, tighter funding markets and operational pressures forcing under‑scaled assets into sales processes. At the same time, competition for high‑quality, high‑growth assets is expected to intensify, with significant deployable capital targeting category leaders in robotics, neuro, advanced diagnostics and data‑rich devices. Recent capital and infrastructure signals Recent European MedTech briefs spotlight a shift from “shiny innovation” to whether innovation survives contact with operational reality, with themes like AI in hospital operations, clinical‑trial infrastructure, and cyber‑resilience (e.g., hospital AI raises, Stryker cyberattack, JenaValve approval) dominating the week of 16–22 March. Earlier 2026 coverage flagged substantial rounds in cardiology (e.g., ~€83m for FineHeart’s implantable heart‑failure device) and AMR diagnostics (e.g., €24m for ShanX Medtech), underlining investor appetite for high‑acuity hardware‑plus‑data and EU‑priority areas.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

This Week in European MedTech and HealthTech: 27th March 2026

OpenClaw is an open-source agentic AI framework that has emerged in 2025–2026 as a leading platform for deploying autonomous AI agents capable of executing tasks across clinical and administrative systems, not just answering queries. Originally known as Moltbot/Clawdbot, it was acquired by OpenAI and has become central to early NHS agentic AI deployments.What OpenClaw Does in HealthcareOpenClaw Component &gt; GatewayConnects to 50+ messaging platforms (Signal, Slack, WhatsApp)NHS Use Case &gt; Clinicians interact via familiar channelsOpenClaw Component &gt; AgentReasoning engine using GPT‑5.2/5.3 modelsNHS Use Case &gt; Translates "Prepare MDT pack for Patient X" into workflowsOpenClaw Component &gt; Skills100+ preconfigured tool bundles (EMR, browsers, files)NHS Use Case &gt; Navigates legacy EHRs at machine speedOpenClaw Component &gt; Heartbeat EngineProactive scheduler (cron-based)NHS Use Case &gt; &nbsp;Monitors vitals/labs overnight, alerts on deteriorationEarly NHS Successes (2025–2026)Guy's and St Thomas': Lung cancer pathway integrating Optellum AI + robotic bronchoscopy, coordinated by OpenClaw agents, replacing weeks of testing with a single targeted procedure.Stroke networks (ESHT/Surrey &amp; Sussex): Real-time brain scan analysis with automated alerts to on-call teams, accelerating treatment decisions.Radiology screening: 124-abnormality chest X-ray detection embedded in standard practice, with agents pushing structured summaries to clinicians.Ambient scribing in ED: Always-on agents generate structured notes, discharge summaries, and code suggestions directly into EMRs.One estimate suggests agentic documentation could save 43 minutes per clinician per day, equating to ~400,000 staff hours/month across the NHS, time redirected to complex, multimorbid patients.Strategic ContextOpenClaw underpins the NHS's "digital-by-default" strategy in the 10-Year Health Plan, aiming to "slash unnecessary bureaucracy". The framework's open-source nature has made it a de facto standard, with vendors integrating rather than building competing agent stacks.However, security analyses highlight risks around endpoint control and data exfiltration if agents aren't tightly sandboxed, critical under NHS data governance. The MHRA's National Commission into AI Regulation (reporting 2026) emphasizes clinician accountability and explainability gaps.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

OpenClaw 2026: NHS Success Stories

10 key talking points expected from Digital Health Rewired 2026 (24th–25th March 2026) at the NEC Birmingham:1) £10bn NHS tech boost and radical digital transformation National leaders will outline how this unprecedented investment is being directed to digitise services at scale despite severe financial and workforce pressures.2) Scaling generative AI across the NHS Real-world case studies in imaging, triage, multidisciplinary teams (MDTs), and research, plus deep discussions on ethics, governance, bias, and procurement of AI tools.3) The “single patient record” and interoperability risks Progress toward a unified view of patient data, the practicalities of combining genomics into records, and the security/interoperability challenges this creates.4) Electronic Patient Record (EPR) benefits realisation With ~90% adoption in England, the focus shifts from implementation to measuring ROI, optimising benefits, and sharing lessons learned from early adopters.5) Digital shift to community and integrated care How digital tools, integrated neighbourhood teams, and shared care records are enabling the NHS 10‑Year Health Plan’s move from hospital to community care.6) Cyber resilience against emerging AI and quantum threats The NHS remains a high-value target; sessions cover legacy IT remediation, cloud/network hardening, cyber skills gaps, and next‑generation threats from AI/quantum computing.7) Digital frontline: supporting a strained workforce New deep-dive case studies show how nursing, midwifery, pharmacy, and AHP teams are using digital to reduce admin burden, improve safety, and work more efficiently.8) Patient engagement, the NHS App and prevention Strategies for inclusive app roll-out, remote monitoring, patient consent and data sharing, and using digital to shift from treatment to early intervention.9) Data-enabled medical research and the Federated Data Platform (FDP) How the NHS is unlocking its world-leading data pool for research, AI enablement, and effective information sharing while maintaining safety and privacy.10 ) Digital leadership and workforce transformation Experiences from chief digital/clinical information officers on building leadership pipelines, developing “genomics champions,” and embedding a digital culture across the health system.These themes directly reflect the three “shifts” of the NHS 10‑Year Health Plan (prevention, community care, and productivity) and are being explored across 10 themed stages with 300+ senior speakers.Source: <a href="https://digitalhealthrewired.com/" data-mce-href="https://digitalhealthrewired.com/">https://digitalhealthrewired.com/</a>

10 Key Talking Points expected from Digital Health ReWired 2026 this week

As of March 2026, the HealthTech M&amp;A landscape has shifted from the "growth at all costs" frenzy of the early 2020s to a regime of Industrial Maturity. Valuations have bifurcated: while general SaaS multiples remain disciplined, a new "X-Factor" premium has emerged for companies that effectively integrate AI into clinical workflows and possess proprietary data moats.The current market is defined by "Regulatory Darwinism," where compliance with the EU AI Act (enforced as of March 2026) and MDR/IVDR standards has become a primary driver of enterprise value.1. Current M&amp;A Valuation Multiples (Q1 2026)Valuations are currently categorized by the "Rule of 40+Data," rewarding companies that balance growth with profitability and defensible data assets.Premium AI &amp; Data PlatformsEV / Revenue Multiple 6.0x – 12.0x+EV / EBITDA Multiple 15x – 20x+Key Valuation Drivers - Proprietary clinical datasets; validated AI; Rule of 40 performance.Value-Based Care (VBC)EV / Revenue Multiple 5.5x – 7.5xEV / EBITDA Multiple 12x – 15xKey Valuation Drivers - Demonstrable ROI for payers; high population health impact.General HealthTech SaaSEV / Revenue Multiple 4.0x – 6.0xEV / EBITDA Multiple 10x – 13xKey Valuation Drivers - Predictable unit economics; stable retention; B2B integration.MedTech / HardwareEV / Revenue Multiple 3.5x – 5.5xEV / EBITDA Multiple 11x – 14xKey Valuation Drivers - MDR/IVDR compliance; "compliance moats"; high barriers to entry.Sub-scale / UnprofitableEV / Revenue Multiple 2.5x – 4.0xEV / EBITDA Multiple N/AKey Valuation Drivers - High burn; lack of clear defensibility; "fire sale" territory.2. Key Variables Driving Valuations in 2026A. The "Compliance Moat" (MDR &amp; EU AI Act)As of March 2026, the full enforcement of the EU AI Act for "high-risk" medical systems has created a binary filter for investors.The Premium: Assets with existing MDR/IVDR certifications and "glass box" (transparent) AI models command a 20-30% premium because they represent immediate market entry for US strategics. The Discount: Non-compliant assets face a 18–24 month regulatory bottleneck, leading to significant valuation compression.B. The AI "X-Factor" and ProductivityBuyers are no longer paying for "AI-enabled" labels. Valuations are now driven by ARR per FTE (Full-Time Equivalent).Companies that use AI to achieve software-like margins (e.g., in RCM, coding, or drug discovery) are seeing their multiples expand. AI-First Drug Discovery remains a high-outlier segment, often trading at 8.0x – 15.0x revenue due to the "bio-bucks" potential and the looming pharmaceutical patent cliff (e.g., Eliquis and Keytruda losing exclusivity).C. Shift to "Unsexy" InfrastructureSmart capital has moved from consumer-facing apps to the "plumbing" of healthcare.Interoperability: Platforms supporting FHIR R4, TEFCA alignment, and clean DICOM support for imaging are highly sought after by PE-backed HCIT consolidators. Workflow Integration: "Point solutions" are being discounted in favor of "systems of action" that sit directly within the clinician's EHR workflow.3. Macro Trends Shaping the March 2026 MarketThe "Trust Gap" is Closing: While HealthTech 2.0 stocks still trade at a 10-15% discount compared to general Cloud SaaS (Bessemer HealthTech Index), the gap is narrowing as companies prove sustainable 60%+ growth with positive FCF. Strategic vs. Financial Buyers: Corporate strategics (e.g., Abbott, Siemens, Roche) are currently paying 25–40% higher multiples than Private Equity firms to fill R&amp;D gaps and secure "compliance moats." The "Use It or Lose It" Dynamic: Many 2021-vintage PE funds are reaching the end of their investment periods, leading to an intensified deal volume in Q1 and Q2 2026 as they deploy remaining dry powder. Note on Value-Based Care (VBC): After a rocky 2024-25, VBC is seeing a "comeback" multiple expansion. Success is now measured by the ability to manage high-cost chronic conditions (Oncology, Cardiology) using AI-driven predictive analytics to reduce hospital readmissions.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a href="mailto:lloyd@nelsonadvisors.co.uk" data-mce-href="mailto:lloyd@nelsonadvisors.co.uk">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

Nelson Advisors featured in Mergermarket: Hims & Hers’ $1...

This Week in European MedTech and HealthTech: 27th March ...

OpenClaw 2026: NHS Success Stories

10 Key Talking Points expected from Digital Health ReWire...

HealthTech M&A Multiples March 2026: Current Trends and V...

The Founder Banker: A New Paradigm in European HealthTech...